Literature DB >> 22354296

In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

Daniel Golparian1, Prabhavathi Fernandes, Makoto Ohnishi, Jörgen S Jensen, Magnus Unemo.   

Abstract

Gonorrhea may become untreatable, and new treatment options are essential. We investigated the in vitro activity of the first fluoroketolide, solithromycin. Clinical Neisseria gonorrhoeae isolates and reference strains (n = 246), including the two extensively drug-resistant strains H041 and F89 and additional isolates with clinical cephalosporin resistance and multidrug resistance, were examined. The activity of solithromycin was mainly superior to that of other antimicrobials (n = 10) currently or previously recommended for gonorrhea treatment. Solithromycin might be an effective treatment option for gonorrhea.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22354296      PMCID： PMC3346660          DOI： 10.1128/AAC.00036-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  39 in total

1.  The European gonococcal antimicrobial surveillance programme, 2009.

Authors:  M J Cole; M Unemo; S Hoffmann; S A Chisholm; C A Ison; M J van de Laar
Journal:  Euro Surveill       Date:  2011-10-20

2.  Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010.

Authors:  C A Ison; J Hussey; K N Sankar; J Evans; S Alexander
Journal:  Euro Surveill       Date:  2011-04-07

3.  The FDA and the case of Ketek.

Authors:  David B Ross
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

4.  The Russian gonococcal antimicrobial susceptibility programme (RU-GASP)--national resistance prevalence in 2007 and 2008, and trends during 2005-2008.

Authors:  A Kubanova; N Frigo; A Kubanov; S Sidorenko; I Lesnaya; S Polevshikova; V Solomka; N Bukanov; M Domeika; M Unemo
Journal:  Euro Surveill       Date:  2010-04-08

5.  Gonococcal resistance: are cephalosporins next?

Authors:  Robert D Kirkcaldy; Ronald C Ballard; Deborah Dowell
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

6.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

7.  Sexually transmitted diseases treatment guidelines, 2010.

Authors:  Kimberly A Workowski; Stuart Berman
Journal:  MMWR Recomm Rep       Date:  2010-12-17

8.  Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010.

Authors:  M Unemo; D Golparian; A Hestner
Journal:  Euro Surveill       Date:  2011-02-10

9.  Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods.

Authors:  John Tapsall; Phillip Read; Christopher Carmody; Christopher Bourne; Sanghamitra Ray; Athena Limnios; Theo Sloots; David Whiley
Journal:  J Med Microbiol       Date:  2009-05       Impact factor: 2.472

10.  Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland.

Authors:  Helen M Palmer; Hugh Young; Andrew Winter; Jayshree Dave
Journal:  J Antimicrob Chemother       Date:  2008-06-13       Impact factor: 5.790
View more
  36 in total

Review 1.  The use of cephalosporins for gonorrhea: an update on the rising problem of resistance.

Authors:  Juliet E Stoltey; Pennan M Barry
Journal:  Expert Opin Pharmacother       Date:  2012-05-30       Impact factor: 3.889

Review 2.  Preparing for an era of untreatable gonorrhea.

Authors:  Lindley A Barbee
Journal:  Curr Opin Infect Dis       Date:  2014-06       Impact factor: 4.915

3.  Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Authors:  Brian D Jamieson; Sabrina Ciric; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

4.  First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea?

Authors:  Magnus Unemo; Daniel Golparian; Bengt Hellmark
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

Review 5.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

6.  Future treatment of gonorrhea--novel emerging drugs are essential and in progress?

Authors:  Magnus Unemo; William M Shafer
Journal:  Expert Opin Emerg Drugs       Date:  2015-07-03       Impact factor: 4.191

7.  Multicenter Investigation of Gepotidacin (GSK2140944) Agar Dilution Quality Control Determinations for Neisseria gonorrhoeae ATCC 49226.

Authors:  Ronald N Jones; Kelley A Fedler; Nicole E Scangarella-Oman; James E Ross; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 8.  Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future.

Authors:  Magnus Unemo; William M Shafer
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

9.  Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.

Authors:  Magnus Unemo; Daniel Golparian; Vegard Skogen; Anne Olaug Olsen; Harald Moi; Gaute Syversen; Stig Ove Hjelmevoll
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

10.  Selective Inhibition of Neisseria gonorrhoeae by a Dithiazoline in Mixed Infections with Lactobacillus gasseri.

Authors:  Jonathan D Lenz; Kristina A Shirk; Adrienne Jolicoeur; Joseph P Dillard
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.